1. Hrbacek J, Cermak P, Zachoval R. Current Antibiotic Resistance Trends of Uropathogens in Central Europe: Survey from a Tertiary Hospital Urology Department 2011-2019. Antibiotics
(Basel) 2020; 9(9): 630.
2. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13(5): 269-284.
3. Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary Tract Infections: The Current Scenario and Future Prospects. Pathogens 2023; 12(4): 623
4. Santos M, Mariz M, Tiago I, Martins J, Alarico S, Ferreira P. A review on urinary tract infections diagnostic methods: Laboratory-based and point-of-care approaches. J Pharm Biomed Anal
2022; 219: 114889.
5. Wagenlehner FME, Bjerklund Johansen TE, Cai T, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol 2020; 17(10): 586-600.
6. Millner R, Becknell B. Urinary Tract Infections. Pediatr Clin North Am 2019; 66(1): 1-13.
7. Kranz J, Bartoletti R, Bruyère F, et al. European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines. Eur Urol 2024; 86(1): 27-41.
8. Dielubanza EJ, Matulewicz RS, Schaeffer AJ. Pyelonephritis and Abscesses of the Kidney. In Cohen, Powderly, Opal, eds. Infectious Diseases. 4th edition. Elsevier; 2017.
9. Brush JL. Pathophysiology of Complicated Urinary Tract Infection (UTI). https://emedicine.medscape.com/article/2039975-overview (erişim 21.03.2024)
10. Drekonja DM. Urinary Tract Infection in Male Patients: Challenges in Management. Infect Dis Clin North Am 2024; 38(2): 311-323.
11. Dickson K, Zhou J, Lehmann C. Lower Urinary Tract Inflammation and Infection: Key Microbiological and Immunological Aspects. J Clin Med 2024; 13(2): 315.
12. Zare M, Vehreschild MJGT, Wagenlehner F. Management of uncomplicated recurrent urinary tract infections. BJU Int 2022; 129(6): 668-678.
13. Sobel JD, Brown P. Urinary Tract Infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA:
Elsevier; 2020.
14. İnan D. İdrar Yolu Enfeksiyonları. In Topçu AW, Söyletir G, Doğanay M (eds). İnfeksiyon Hastalıkları ve Mikrobiyolojisi, 4. Baskı. İstanbul: Nobel Tıp Kitabevi;2017
15. Cooper KL, Badalato GM, rutman P. Infections of the Urinary Tract. In: Partin AW, Peters CA, Kavoussi LR, Dmochowski RR, Wein AJ, editors. Campbell-Walsh urology. 12th edition. Phi-
ladelphia: Elsevier; 2020.
16. Sabih A, Leslie SW. Complicated Urinary Tract Infections. [Updated 2023 November 12]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.
17. Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother 2021; 27(8): 1131-1136.
18. Gravestock P, Moore L, Harding C, Veeratterapillay R. Xanthogranulomatous pyelonephritis: a review and meta-analysis with a focus on management. Int Urol Nephrol 2022; 54(10): 2445-
2456.
19. Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2017; 129(2): 242-258.
20. Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol 2020; 38(11): 2669-2679.
21. Nicolle LE. Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int Antimicrob Agents 2006; 28: 42-48i.
22. Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic bacteriuria in adults. Am Fam Physician 2006; 74: 985–990
23. Fisher JF, Kavanagh K, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infection: pathogenesis. Clin Infect Dis 2011 Suppl 6: S437-51.
24. Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am 2014; 28(1): 61-74.
25. Kenneally C, Murphy CP, Sleator RD, Culligan EP. The urinary microbiome and biological therapeutics: Novel therapies for urinary tract infections. Microbiol Res 2022; 259: 127010.
26. Lazarus JE, Gupta K. Recurrent UTI in Women-Risk Factors and Management. Infect Dis Clin North Am 2024;38(2): 325-341.
27. Tesini BL, Dumyati G. Health Care-Associated Infections in Older Adults: Epidemiology and Prevention. Infect Dis Clin North Am 2023; 37(1): 65-86.
28. Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother 2021;27 (8): 1131-1136.
29. Fu EL, D’Andrea E, Wexler DJ, Patorno E, Paik JM. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study. Clin
J Am Soc Nephrol 2023; 18(5): 592–601.
30. Zheng Z, He D, Chen J, et al. Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized
Controlled Trials. Clin Drug Investig. 2023; 43(4): 209-225.
31. Fitzpatrick MA, Nwafo N. Urinary Tract Infection Diagnostic and Management Considerations in People with Spinal Cord Injury and Neurogenic Bladder. Infect Dis Clin North Am 2024;
38(2): 381-393.
32. Kalinderi K, Delkos D, Kalinderis M, Athanasiadis A, Kalogiannidis I. Urinary tract infection during pregnancy: current concepts on a common multifaceted problem. J Obstet Gynaecol
2018; 38(4): 448-453.
33. Daurte G, Marcolin AC, Quintana SM, Cavalli RC. Urinary tract infection in pregnancy. Rev Bras Ginecol Obstet 2008; 30(2): 93-100.
34. Patterson TF, Andriole VT. Detection, significance, and therapy of bacteriuria in pregnancy. Update in the managed health care era. Infect Dis Clin North Am 1997; 11: 593-608.
35. McAteer J, Tamma PD. Diagnosing and Managing Urinary Tract Infections in Kidney Transplant Recipients. Infect Dis Clin North Am 2024; 38(2): 361-380.
36. Shuman EK, Chenoweth CE. Urinary Catheter-Associated Infections. Infect Dis Clin North Am 2018; 32(4): 885-897.
37. Nicolle LE. Asymptomatic bacteriuria: When to screen and when to treat? Infect Dis Clin N Am 2003; 17: 367–394.
38. Siegel SR, Siegel B, Sokoloff BZ, Kanter MH. Urinary infection in infants and preschool children. Five-year follow-up. Am J Dis Child 1980; 134: 369–372.
39. Akhter AJ, Andrews GR, Caird FJ, Fallon RJ. Urinary tract infection in the elderly: a population study. Age Ageing 1972; 1: 48–54.
40. Stamm WS. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991; 91 (suppl B): S65–71.
41. Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 1982; 146:
719–723.
42. Brandström P, Hansson S. Urinary Tract Infection in Children. Pediatr Clin North Am 2022; 69(6): 1099-1114.
43. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 Suppl 1A:5S-13S.
44. Peck J, Shepherd JP. Recurrent Urinary Tract Infections: Diagnosis, Treatment, and Prevention. Obstet Gynecol Clin North Am 2021; 48(3): 501-513.
45. Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging health 2013; 9(5): 10.2217/ahe.13.38.
46. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28: 1–13.
47. Kaur R, Kaur R. Symptoms, risk factors, diagnosis and treatment of urinary tract infections. Postgrad Med J. 2021; 97(1154): 803-812.
48. McLellan LK, Hunstad DA. Urinary Tract Infection: Pathogenesis and Outlook. Trends Mol Med. 2016; 22(11): 946-957.
49. Dubbs SB, Sommerkamp SK. Evaluation and Management of Urinary Tract Infection in the Emergency Department. Emerg Med Clin North Am. 2019 Nov;37(4):707-723
50. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: a population-based assessment. Infection 2007; 35(3): 150-153.
51. Takhar SS, Moran GJ. Diagnosis and management of urinary tract infection in the emergency department and outpatient settings. Infect Dis Clin North Am 2014;28(1): 33-48.
52. Smaill F. Asymptomatic bacteriuria in pregnancy. Best Pract Res Clin Obstet Gynaecol 2007; 21(3): 439-450.
53. Stapleton AE. Urinary tract infection pathogenesis: host factors. Infect Dis Clin North Am 2014; 28(1): 149-159.
54. Ljubetic BM, Mohammad A, Durrani B, Dobberfuhl AD. Pathophysiologic Insights into the Transition from Asymptomatic Bacteriuria to Urinary Tract Infection. Curr Urol Rep. 2023
Nov;24(11):533-540.
55. Grey B, Upton M, Joshi LT. Urinary tract infections: a review of the current diagnostics landscape. J Med Microbiol. 2023 Nov;72(11).
56. Johnson JR, Orskov I, Orskov F, et al. O, K, and H antigens predict virulence factors, carboxylesterase B pattern, antimicrobial resistance, and host compromise among Escherichia coli strains
causing urosepsis. J Infect Dis 1994; 169: 119–126
57. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4(1): 80-128.
58. Johnson JR, Roberts PL, Stamm WE. P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients’ characteristics. J Infect Dis 1987; 156(1): 225-229.
59. Johnson JR, Kuskowski MA, Gajewski A, Soto S, Horcajada JP, Jimenez de Anta MT, Vila J. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from
patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis 2005; 191(1): 46-50.
60. Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol 2020; 18(4): 211-226.
61. Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y, Huang Y, Chi M. Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol
Sci 2023; 24(13): 10537.
62. Mayrier A. Bacterial adherence and other virulence factors for urinary tract infection. https://www.uptodate.com/contents/bacterial-adherence-and-other-virulence-factors-for-u-
rinary-tract-infection?search=Bacterial%20adherence%20and%20other%20virulence%20factors%20for%20urinary%20tract%20infection&source=search_result&selectedTit-
le=1%7E150&usage_type=default&display_rank=1 (Erişim 20.01.2024).
63. Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int 2007; 72(1):
19-25.
64. Chieng CCY, Kong Q, Liou NSY, Khasriya R, Horsley H. The clinical implications of bacterial pathogenesis and mucosal immunity in chronic urinary tract infection. Mucosal Immunol 2023;
16(1): 61-71.
65. Neugent ML, Hulyalkar NV, Nguyen VH, Zimmern PE, De Nisco NJ. Advances in Understanding the Human Urinary Microbiome and Its Potential Role in Urinary Tract Infection. mBio
2020; 11(2): e00218-20.
66. Engel DR, Wagenlehner FME, Shevchuk O. Scientific Advances in Understanding the Pathogenesis, Diagnosis, and Prevention of Urinary Tract Infection in the Past 10 Years. Infect Dis Clin
North Am 2024; 38(2): 229-240.
67. Duell BL, Carey AJ, Tan CK, et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of
IL-10 for defense against bacterial urinary tract infection. J Immunol 2012;188(2): 781-792.
68. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 2008;
10(12): 2568-2578.
69. Sivick KE, Schaller MA, Smith SN, Mobley HL. The innate immune response to uropathogenic Escherichia coli involves IL-17A in a murine model of urinary tract infection. J Immunol 2010;
184(4): 2065-2075.
70. Schiwon M, Weisheit C, Franken L, et al. Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium. Cell 2014; 156(3): 456-468.
71. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998; 282(5393): 1494-1497.
72. Schaale K, Peters KM, Murthy AM, et al. Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Esc-
herichia coli. Mucosal Immunol 2016; 9(1): 124-136.
73. Zaffanello M, Malerba G, Cataldi Let al. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J Biomed Biotechnol 2010; 2010: 321082.
74. Isali I, Wong TR, Batur AF, et al. Recurrent urinary tract infection genetic risk: a systematic review and gene network analysis. Int Urogynecol J 2024; 35(2): 259-271.
75. Chen YC, Lee WC, Chuang YC. Emerging Non-Antibiotic Options Targeting Uropathogenic Mechanisms for Recurrent Uncomplicated Urinary Tract Infection. Int J Mol Sci 2023; 24(8):
7055.
76. Kim DS, Lee JW. Urinary Tract Infection and Microbiome. Diagnostics (Basel) 2023; 13(11): 1921.
77. Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, Kliethermes S, Schreckenberger PC, Brubaker L, Gai X, Wolfe AJ. The female urinary microbiome: a comparison of
women with and without urgency urinary incontinence. mBio 2014 8; 5(4): e01283-1314.
78. Modena BD, Milam R, Harrison F, Cheeseman JA, Abecassis MM, Friedewald JJ, Kirk AD, Salomon DR. Changes in Urinary Microbiome Populations Correlate in Kidney Transplants
With Interstitial Fibrosis and Tubular Atrophy Documented in Early Surveillance Biopsies. Am J Transplant 2017; 17(3): 712-723.
79. Bi H, Tian Y, Song Cet al. Urinary microbiota – a potential biomarker and therapeutic target for bladder cancer. J Med Microbiol 2019; 68(10): 1471-1478.
80. Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, Albakry S, Satlin MJ, Westblade LF, Crawford C, Dadhania DM, Lubetzky M, Taur Y, Littman E, Ling L, Burnham P, De Vlaminck
I, Pamer E, Suthanthiran M, Lee JR. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun 2019; 10(1): 5521.
81. Komesu YM, Richter HE, Carper B, Dinwiddie DL, Lukacz ES, Siddiqui NY, Sung VW, Zyczynski HM, Ridgeway B, Rogers RG, Arya LA, Mazloomdoost D, Gantz MG; Pelvic Floor Disorders
Network. The urinary microbiome in women with mixed urinary incontinence compared to similarly aged controls. Int Urogynecol J. 2018; 29(12):1785-1795.
82. Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr 2016; 4(6): 10.1128/microbiolspec.UTI-0025-2016.
83. Nicolle LE. Complicated Urinary Infection, Including Postsurgical and Catheter-Related Infections. In Cohen, Powderly, Opal, eds. Infectious Diseases. 4th edition. Elsevier; 2017.
84. Brehm TJ, Trautner BW, Kulkarni PA. Acute and Chronic Infectious Prostatitis in Older Adults. Infect Dis Clin North Am. 2023 Mar;37(1):175-194.
85. Fitzpatrick MA, Nwafo N. Urinary Tract Infection Diagnostic and Management Considerations in People with Spinal Cord Injury and Neurogenic Bladder. Infect Dis Clin North Am 2024;
38(2): 381-393.
86. Bilsen MP, Aantjes MJ, van Andel E,et al. Current Pyuria Cutoffs Promote Inappropriate Urinary Tract Infection Diagnosis in Older Women. Clin Infect Dis 2023; 76(12): 2070-2076.
87. Dean AJ, Lee DC. Bedside laboratory and microbiologic procedures. In: Roberts JR, Hedges JR, Custalow CB, eds. Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute
Care, 7th edition. Philadelphia: Elsevier; 2019.
88. Tullus K, Shaikh N. Urinary tract infections in children. Lancet 2020; 395(10237): 1659-1668.
89. Williams GJ, Macaskill P, Chan SF, Turner RM, Hodson E, Craig JC. Absolute and relative accuracy of rapid urine tests for urinary tract infection in children: a meta-analysis. Lancet Infect
Dis 2010; 10(4):240-250.
90. Mayrier A. Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults. https://www.uptodate.com/contents/sampling-and-evaluation-of-voided-uri-
ne-in-the-diagnosis-of-urinary-tract-infection-in-adults?search=urinary%20tract%20infection%20and%20diagnosis&source=search_result&selectedTitle=2%7E150&usage_type=defa-
ult&display_rank=2
91. Redwood R, Claeys KC. The Diagnosis and Treatment of Adult Urinary Tract Infections in the Emergency Department. Emerg Med Clin North Am 2024; 42(2): 209-230.
92. Chernaya A, Søborg C, Midttun M. Validity of the urinary dipstick test in the diagnosis of urinary tract infections in adults. Dan Med J 2021; 69(1): A07210607.
93. Al Lawati H, Blair BM, Larnard J. Urinary Tract Infections: Core Curriculum 2024. Am J Kidney Dis 2024; 83(1): 90-100.
94. Sabih A, Leslie SW. National Libray of Medicine. Complicated urinary tract infections. In StatPearls. Treasure Island (FL); 2023.
95. Grey B, Upton M, Joshi LT. Urinary tract infections: a review of the current diagnostics landscape. J Med Microbiol 2023; 72(11).
96. Dull RB, Friedman SK, Risoldi ZM, Rice EC, Starlin RC, Destache CJ. Antimicrobial treatment of asymptomatic bacteriuria in noncatheterized adults: a systematic review. Pharmacotherapy
2014; 34(9): 941-960.
97. Nicolle LE. Asymptomatic bacteriuria. Curr Opin Infect Dis 2014; 27(1): 90-96.
98. Nicolle LE, Bradley S, Colgan R, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect
Dis 2019;68(10): e83-e110.
99. Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer.
Lancet Infect Dis 2017; 17(11): e344-e356.
100. Petrosillo N, Granata G, Boyle B, Doyle MM, Pinchera B, Taglietti F. Preventing sepsis development in complicated urinary tract infections. Expert Rev Anti Infect Ther 2020; 18(1): 47-61.
101. Ferreira L, Sanchez-Juanes F, Gonzalez-Avila M, Cembrero-Fucinos D, Herrero-Hernandez A, et al. Direct identification of urinary tract pathogens from urine samples by matrix-assisted laser
desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2010; 48: 2110–2115.
102. Yassin A, Kaye KS, Bhowmick T. Unitary Tract Infection Treatment: When to Use What Agents including Beta-lactam Combination Agents. Infect Dis Clin North Am 2024; 38(2): 295-310.
103. Köves B, Cai T, Veeratterapillay R, et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology
Urological Infection Guidelines Panel. Eur Urol 2017; 72(6): 865-868.
104. Irfan N, Brooks A, Mithoowani S, Celetti SJ, Main C, Mertz D. A Controlled Quasi-Experimental Study of an Educational Intervention to Reduce the Unnecessary Use of Antimicrobials For
Asymptomatic Bacteriuria. PLoS One 2015; 10(7): e0132071.
105. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 2012; 55 (6): 771–777.
106. Nicolle LE. Reducing Treatment of Asymptomatic Bacteriuria: What Works? Infect Dis Clin North Am 2024; 38(2): 267-276.
107. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 2012; 55(6): 771-777.
108. Asscher AW, Sussman M, Waters WE, et al. Asymptomatic significant bacteriuria in the non-pregnant woman II. Response to treatment and follow-up. BMJ 1969; 1: 804–806.
109. Nicolle LE. The Paradigm Shift to Non-Treatment of Asymptomatic Bacteriuria. Pathogens 2016; 5 (2): 38.
110. Rao Z, Wang Z, Tang M, Shen L, Zhang K. Treatment of Asymptomatic Bacteriuria after Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Medicina (Kaunas) 2023; 59(9): 1600.
111. Medina-Polo J, Falkensammer E, Köves B, et al. Systematic Review and Meta-Analysis Provide no Guidance on Management of Asymptomatic Bacteriuria within the First Year after Kidney
Transplantation. Antibiotics (Basel) 2024; 13(5): 442.
112. Grabe M, Forsgren A, Bjork T, Hellsten S. Controlled trial of a short and a prolonged course with ciprofloxacin in transurethral prostatic surgery. Eur J Clin Microbiol 1987; 6: 11–7.
113. Olsen JH, Friis-Moller A, Jensen SK, Korner B, Hvidt V. Cefotaxime for prevention of infectious complications in bacteriuric men undergoing transurethral prostatic resection. A controlled
comparison with methenamine. Scand J Urol Nephrol 1983; 17: 299–301.
114. Grabe M, Forsgren A, Hellsten S. The effect of a short antibiotic course in transurethral prostatic resection. Scand J Urol Nephrol 1984; 18: 37–42.
115. Sayin Kutlu S, Aybek Z, Tekin K, et al. Is short course of antimicrobial therapy for asymptomatic bacteriuria before urologic surgical procedures sufficient? J Infect Dev Ctries 2012; 6(2): 143-
147.
116. Kutlu M, Arslan M, Ozlulerden Y, Ozdemir K, Sayin-Kutlu S, Aybek Z. A short course of antimicrobial therapy for asymptomatic bacteriuria is safe and effective before urologic procedures.
J Infect Dev Ctries 2021; 15(5) :742-746.
117. Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2015;(8):CD000490.
118. Gratacos E, Torres PJ, Vila J, et al. Screening and treatment of asymptomatic bacteriuria in pregnancy prevent pyelonephritis. J Infect Dis. 1994;169:1390-2.
119. Smaill F. Asymptomatic bacteriuria in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2007; 21: 439-50.
120. Kazemier BM, Koningstein FN, Schneeberger C, et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with
an embedded randomised controlled trial. Lancet Infect Dis 2015; 15(11): 1324-1333.
121. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;
62(4): e1-50.
122. Georgiadou SP, Tarrand J, Sipsas NV, Kontoyiannis DP. Candiduria in haematologic malignancy patients without a urinary catheter: nothing more than a frailty marker? Mycoses 2013; 56:
311–314.
123. Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020 Apr;132(3):234-250
124. Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the
treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infecti-
ous Diseases. Clin Infect Dis 2011; 52(5): e103–120.
125. Kang CI, Kim J, Park DW, et al. Clinical Practice Guidelines for the Antibiotic Treatment of Community-Acquired Urinary Tract Infections. Infect Chemother 2018; 50(1): 67-100.
126. Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, Amy J. Mathers, Michael J. Satlin, Robert A. Bonomo, Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance:
Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2024; Versiyon 4.0. https://www.idsociety.org/practice-guideline/amr-guidance/. Erişim 23.07.2024.
127. López-Montesinos I, Horcajada JP. Oral and intravenous fosfomycin in complicated urinary tract infections. Rev Esp Quimioter 2019; 32 Suppl 1(Suppl 1): 37-44.
128. Kayaaslan B, Oktay Z, Hasanoglu I, et al. Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute
pyelonephritis and evaluation of empirical treatments based on culture results. Eur J Clin Microbiol Infect Dis 2022; 41(3): 421-430.
129. Tüzün T, Sayın Kutlu S, Kutlu M, Kaleli İ. Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Turk J Med Sci
2019; 49(4): 1206-1211.
130. Perera PDVM, Gamage S, De Silva HSM, et al. Phenotypic and genotypic distribution of ESBL, AmpC β-lactamase and carbapenemase-producing Enterobacteriaceae in community-acquired
and hospital-acquired urinary tract infections in Sri Lanka. J Glob Antimicrob Resist 2022; 30: 115-122.
131. Jia P, Zhu Y, Li X, Kudinha T, Yang Y, Zhang G, Zhang J, Xu Y, Yang Q. High Prevalence of Extended-Spectrum Beta-Lactamases in Escherichia coli Strains Collected From Strictly Defined
Community-Acquired Urinary Tract Infections in Adults in China: A Multicenter Prospective Clinical Microbiological and Molecular Study. Front Microbiol. 2021 Jul 7;12:663033.
132. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled,
non-inferiority trial. Lancet 2012; 380(9840) :484-490.
133. Dinh A, Davido B, Etienne M, et al. Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial. Eur J Clin Microbiol Infect Dis 2017; 36(8):
1443-1448.
134. Kranz J, Schmidt S, Lebert C, et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract
Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int 2018; 100(3): 271-278.
135. Rudrabhatla P, Deepanjali S, Mandal J, Swaminathan RP, Kadhiravan T. Stopping the effective non-fluoroquinolone antibiotics at day 7 vs continuing until day 14 in adults with acute pyelo-
nephritis requiring hospitalization: A randomized non-inferiority trial. PLoS One 2018; 13(5): e0197302.
136. Fox MT, Melia MT, Same RG, Conley AT, Tamma PD. A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. Am
J Med 2017; 130(7): 842-845.
137. Erba L, Furlan L, Monti A, et al. Short vs long-course antibiotic therapy in pyelonephritis: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. Intern
Emerg Med 2021; 16(2): 313-323.
138. Germanos GJ, Trautner BW, Zoorob RJ, et al. No Clinical Benefit to Treating Male Urinary Tract Infection Longer Than Seven Days: An outpatient Database Study. Open Forum Infect Dis
2019; 6(6): ofz216.
139. Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis 2016; 63: 960–965.
140. Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. J Infect Chemother 2021; 27(8): 1131-1136.
141. Hooton TM, Vecchio M, Iroz A, et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Intern
Med 2018; 178(11): 1509-1515.
142. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008; (2): CD005131.
143. Lazarus JE, Gupta K. Recurrent UTI in Women-Risk Factors and Management. Infect Dis Clin North Am 2024; 38(2): 325-341.
144. Goddard, J.C., et al. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J 2018; 29(7): 933-942.
145. Li JM, Cosler LE, Harausz EP, Myers CE, Kufel WD. Methenamine for urinary tract infection prophylaxis: A systematic review. Pharmacotherapy 2024; 44(2): 197-206.
146. Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract
infection. Clin Infect Dis 2011; 52(10): 1212-1217.
147. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of rando-
mized controlled trials. J Urol 2013; 190(6): 1981-1989.
148. Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. NEJM Evid 2022; 1(4): EVIDoa2100018
149. Nickel JC, Doiron RC. An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women. Pathogens 2023; 12(3): 359.
150. Prattley S, Geraghty R, Moore M, Somani BK. Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review. Eur Urol Focus 2020; 6(3): 593-604.
151. Nestler S, Grüne B, Schilchegger L, Suna A, Perez A, Neisius A. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. Int
Urol Nephrol 2021; 53(11): 2267-2272.
152. Mak Q, Greig J, Dasgupta P, Malde S, Raison N. Bacterial Vaccines for the Management of Recurrent Urinary Tract Infections: A Systematic Review and Meta-analysis. Eur Urol Focus 2024:
S2405-4569(24)00054-3.
153. Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and Prevention of Recurrent Lower Urinary Tract Infections in Women: A Rapid Review with Practice Re-
commendations. J Urol 2018; 200(6): 1174-1191.
154. Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol 2018; 15(12): 750-776